Johnson & Johnson (NYSE:JNJ) Shares Sold by DT Investment Partners LLC

DT Investment Partners LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 59,401 shares of the company’s stock after selling 4,647 shares during the period. Johnson & Johnson accounts for 0.7% of DT Investment Partners LLC’s portfolio, making the stock its 27th largest position. DT Investment Partners LLC’s holdings in Johnson & Johnson were worth $8,591,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CFC Planning Co LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $1,920,000. Compagnie Lombard Odier SCmA boosted its stake in Johnson & Johnson by 9.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 312,962 shares of the company’s stock valued at $45,261,000 after acquiring an additional 26,731 shares during the last quarter. Root Financial Partners LLC boosted its stake in Johnson & Johnson by 218.2% during the 4th quarter. Root Financial Partners LLC now owns 8,972 shares of the company’s stock valued at $1,298,000 after acquiring an additional 6,152 shares during the last quarter. Newport Capital Group LLC boosted its stake in Johnson & Johnson by 8.8% during the 4th quarter. Newport Capital Group LLC now owns 3,464 shares of the company’s stock valued at $501,000 after acquiring an additional 279 shares during the last quarter. Finally, IMS Capital Management boosted its stake in Johnson & Johnson by 18.4% during the 4th quarter. IMS Capital Management now owns 18,191 shares of the company’s stock valued at $2,631,000 after acquiring an additional 2,823 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ opened at $156.20 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm’s 50 day moving average price is $147.87 and its 200 day moving average price is $155.95. The firm has a market cap of $376.08 billion, a PE ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.